Combating drug resistance in hepatocellular carcinoma: No awareness today, no action tomorrow

Jing, Fanbo; Li, Xiao; Jiang, Hui; Sun, Jialin; Guo, Qie

doi:10.1016/j.biopha.2023.115561

Cited by 2 publications

(1 citation statement)

References 173 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CA3 is another small molecule that inhibits YAP and has been proposed as an anticancer agent against HCC (Han et al 2022 ). Enhanced expression of cyclin-dependent kinase 6 (CDK6) has been proposed as one of the main causes of lenvatinib resistance in HCC (Leung et al 2023 ; Jing et al 2023 ). A recent study showed that CA3 effectively inhibits CDK6 expression, demonstrating the potential of YAP/TAZ inhibitors in combination therapy for HCC (Leung et al 2023 ).…”

Section: Drug Candidates Targeting Yap/taz In the Livermentioning

confidence: 99%

Interplay between YAP/TAZ and metabolic dysfunction-associated steatotic liver disease progression

Lee,

Choi,

Lee

et al. 2024

Arch. Pharm. Res.

View full text Add to dashboard Cite

Metabolic dysfunction-associated steatotic liver disease (MASLD) is becoming an increasingly pressing global health challenge, with increasing mortality rates showing an upward trend. Two million deaths occur annually from cirrhosis and liver cancer together each year. Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), key effectors of the Hippo signaling pathway, critically regulate tissue homeostasis and disease progression in the liver. While initial studies have shown that YAP expression is normally restricted to cholangiocytes in healthy livers, the activation of YAP/TAZ is observed in other hepatic cells during chronic liver disease. The disease-driven dysregulation of YAP/TAZ appears to be a critical element in the MASLD progression, contributing to hepatocyte dysfunction, inflammation, and fibrosis. In this study, we focused on the complex roles of YAP/TAZ in MASLD and explored how the YAP/TAZ dysregulation of YAP/TAZ drives steatosis, inflammation, fibrosis, and cirrhosis. Finally, the cell-type-specific functions of YAP/TAZ in different types of hepatic cells, such as hepatocytes, hepatic stellate cells, hepatic macrophages, and biliary epithelial cells are discussed, highlighting the multifaceted impact of YAP/TAZ on liver physiology and pathology.

show abstract